* The drug Vaxira Racotumomab, created by researchers at the Center of Molecular Immunology (CIM) in Cuba, recorded in 2012, is the second product from advanced lung cancer non-small cell, the most frequent and deadly.
* In 2011, after demonstrating its efficacy in a clinical trial in Cuba, Racotumomab received the certificate of approval for use, granted by the State Center for Quality Control of Medicines (CECMED) of Cuba.
* Since January 2013 is applied in primary care in Cuba. In March a new trial, polyclinics level with 700 patients.
* Congress of the European Society for Medical Oncology (Vienna, 2012) gave the CIM distinction relevant result for his presentation on the use of Racotumomab.
* Authorship Racotumomab patent corresponds to researchers at the Center of Molecular Immunology Cuba, which grants a license to use the Argentine counterparts.
* Racotumomab production takes place and continue to take place in the MIC of Cuba.
• The main author of this important scientific achievement is Dr. Ana María Vázquez López, researcher at the Center of Molecular Immunology in Cuba.
By Orfilio Pelaez
Racotumomab (VAXIRA), the innovative drug was created by researchers at the Center of Molecular Immunology, following the favorable results of a clinical trial of effectiveness in our country led by the National Coordinating Center for Clinical Trials, conducted with 176 patients between 2008 and 2011 in hospitals Celestino Hernandez, Santa Clara, Jose Ramon Lopez Tabranes Matanzas, and the National Institute of Oncology and Radiobiology, received the certificate of approval for use, granted by the State Center for Control Quality of Medicines (CECMED).
As explained Dr. Tania Crombet Granma, Clinical Research Director of the Center of Molecular Immunology, the new vaccine which is administered intradermally reported an increased survival time in patients who were administered, compared with the control group did not.
According to the scientist said, the product is also…very low toxicity, not cause the unpleasant side effects of chemotherapy and radiotherapy.This allows long-term treatment to elderly patients, that when they have a lung carcinoma are sometimes not eligible for cytostatics.
The favorable drug safety apply in primary health care.Since last January, is running a new test level polyclinics, which should include about 700 patients.
By getting this second therapeutic vaccine (the first was CIMAvax-EGF achieved at the Centre and registered in 2008), Cuba became the only country in the world in having two drugs validated by national regulatory authorities to treat cancer lung.
The goal is to transform advanced cancer into a chronic disease that can be controlled for long periods, as with diabetes or hypertension, the sick providing more years of survival and quality of living.
The presentation of the experience of the Center of Molecular Immunology in using Racotumomab received the distinction of relevant results in the last Congress of the European Society for Medical Oncology (ESMO for its acronym in English), held in Vienna, Austria, in 2012 .
It has also been published in prestigious international journals, including The Journal of Immunology, American Society for Immunology, and Clinical Immunology.
During the exchange with reporters, Dr. Tania Crombet said that currently is running a multinational, involving institutions of Cuba, Argentina, Brazil, Indonesia, Singapore and Uruguay.
Also, in our country and smaller scale runs another which combines the two vaccines achieved in the Molecular Immunology Center, the results are encouraging from the point of view of the antitumor immune response.
NEXT LAUNCH IN ARGENTINA
The result of a collaboration that began in 1994 with the company Elea, who achieved greater dimension to become the 2003 Cuban joint venture RECOMBIO Argentina, the South American country’s regulatory agency ANMAT approved in March of this year the vaccine record Racotumomab.
He stressed that all production of the vaccine continue to be made in Cuba.The authorship of the patent belongs to researchers at the Center of Molecular Immunology